Review Article

Vitamin D Receptor Agonists: Suitable Candidates as Novel Therapeutic Options in Autoimmune Inflammatory Myopathy

Clara Crescioli

Section of Health Sciences, Department of Movement, Human and Health Sciences, University of Rome Foro Italico, 00135 Rome, Italy

Correspondence should be addressed to Clara Crescioli; clara.crescioli@uniroma4.it

Received 27 December 2013; Accepted 9 April 2014; Published 7 May 2014

Academic Editor: Marina Bouché

Copyright © 2014 Clara Crescioli. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

The primary aim in the treatment of autoimmune inflammatory myopathies (IMs) is to recover muscle function. The presence of immune/inflammatory cell infiltrates within muscle tissues represents the common feature of different IM subtypes, albeit a correlation between muscular damage extent and inflammation degree is often lacking. Treatments for IMs are based on life-long immunosuppressive therapy, with the well known adverse effects; recovery is incomplete for many patients. More effective therapies, with reduced side-effects, are highly desirable. Vitamin D receptor (VDR) agonists emerge to retain pleiotropic anti-inflammatory properties, since they regulate innate and adaptive immunity by switching the immune response from proinflammatory Th1 type to tolerogenic Th helper 2 (Th2) type dominance. In skeletal muscle cells less hypercalcemic VDR ligands target powerful mediators of inflammation, such as TNFα and TNFα driven paths, without affecting immune or muscle cells viability, retaining the potentiality to counteract Th1 driven overreactivity established by the self-enhancing inflammatory loop between immune and skeletal muscle cells. This review summarizes those features of VDR agonists as candidates in future treatment of IM.

1. Introduction

Increasing evidence points out that vitamin D, beside bone metabolism and calcium homeostasis regulation, plays a pivotal role in maintaining the functionality of many other tissues, including skeletal muscle. A direct association of vitamin D status with skeletal muscle fiber composition, muscle power and force, or physical performance has been documented by several studies in old or young human population [1, 2]; remarkably, vitamin D supplementation is associated with improvements in muscle performance and fall reduction [1, 3–6].

Experimental models of VDR null mutant mice document diffused muscle fiber abnormalities and severe alterations in muscle cell differentiation or fiber development/maturation [7–9]; in humans, VDR gene polymorphisms have been associated with muscle strength defects, as recently reported [1, 10]. Direct effects of vitamin D on muscle cell proliferation, differentiation, and myotube size have been recently proposed in a murine experimental in vitro model [11]. Skeletal muscle is a well known target tissue of vitamin D action and the association between severe vitamin D deficiency and myopathy has been recognized since and recently confirmed [1, 12]. Myopathy is characterized by severe myofiber degeneration and muscle wasting; in particular, IMs are a wide range of autoimmune diseases, collectively known as myositis, characterized clinically by reduced muscle endurance and weakness, chronic inflammation, and infiltration by immune/inflammatory cells in skeletal muscles. Since both adaptive and innate immunity are involved in IMs, the mainstay treatment is directed to suppress or modify immune cell activity and is based on high dose corticosteroid combined with immunosuppressive drugs, as steroid-sparing agents [13–15]. However, most of IM patients have just a partial clinical improvement, few recover muscle performance, and about 25% are refractory to those drugs and left with disability [13–15], suggesting that pharmacological targeting the immune system may be not enough for satisfactory therapeutic effects.

Much more interest has been recently addressed to the muscular component, as an active counterpart dialoguing with the immune system during inflammation throughout
the production of cytokines and chemokines, highly chemo-
tactic peptides. In this light, skeletal muscle cells, behaving as
immunoactive structures, could be also hypothesized to be
therapeutic targets as well.

Advances in clinical and bench research highlight the vit-
amin D impact on muscle function and morphology, either in
physiologic or pathologic conditions [16–18]; also, VDR ago-
nists emerge to exert pleiotropic activities in (auto)immune
regulation by both immune and resident cells [19–
21].

This review aims to offer an overview on VDR agonists
as potential novel therapeutic tools to control inflammation
in IMs; in particular, biomolecular pathway(s) and inflam-
matory mediators within skeletal muscle cells engaged in IM
pathogenesis, such as the cytokine TNFα and the chemokine
CXCL10, will be discussed as intracellular pharmacological
(target(s) of nonhypercalcemic VDR agonists.

2. Pathogenic Mechanisms of IMs
IMs are a heterogeneous group of systemic autoimmune
diseases classified in distinct subgroups, that is, idiopathic
dermatomyositis (DM), polymyositis (PM), inclusion body
myositis (IBM), the most studied ones, necrotizing autoim-
mune myositis, and myositis associated with systemic disor-
ders on the basis of some clinical and histological differences
[22–24]. Muscle weakness, fatigue, and elevated serum mus-
cle enzymes, together with myofiber degeneration/fibrosis
and mononuclear cell infiltration represent, respectively,
clinical and histological features common to all subtypes.

Different pathogenic mechanisms have been hypothe-
sized due to distinct predominating localization/phenotype
of the inflammatory infiltrates, that is, while a striking
dominance of CD4+ T cells has been reported at perivas-
cular/perimysial sites, as often found in DM, endomysial
infiltrates are dominated by CD8+ T cells, as more frequently
observed in PM and IBM; the presence of B lymphocytes,
which seem to preferentially target the microvascular com-
ponent in DM, is considered less critical in PM [25]. Those
differences, however, appear to be an oversimplification of
the reality: an overlap between clinical phenotypes, immuno-
types, and histopathology has been often depicted and fre-
quently mirrors an overlap in diagnostic criteria as well [15,
25–27]. The inflammatory molecules and mediators involved
in muscles affected by myositis are highly similar, given that
some essential molecular paths engaged in immune response
(innate and adaptive) are shared between the different IM
subsets. The presence of autoantibodies, frequently detected
in PM and DM, autoreactive lymphocytes, together with
overexpression of major histocompatibility complex (MHC,
or HLA, human leucocyte antigen) molecules on the surface
of the affected myofibers albeit, at different degree,
represent common traits of immune-mediated diseases. HLA
molecules mediate the immune response by presenting pro-
cessed antigen peptides, either self- or not-self, to activated T
cells. In particular, T cells with Th1 immune reaction predom-
nance, macrophages, and dendritic cells (DC) are found in
muscles of the different subgroups of IMs [25, 28]. The pre-
ence of B lymphocytes, natural killer (NK) cells, or antigen
presenting cell (APC) other than DC—such as endothelial
or skeletal muscle cells themselves—have been also observed
in all types of IMs [29–31]. However, albeit pathogenic
mechanisms still are unclear, Th1 cells and macrophages play
a pivotal role in IM pathogenesis: their local accumulation
likely contributes to the deposition of immune complexes
within skeletal muscles [32, 33] through the release of func-
tional molecules, such as cytokines and chemokines; once
present within the muscular microenvironment, they are able
to cause damages directly to fibers and capillaries of the
affected muscles [34]. The expression of cytokines as IFNy,
TNFα, and several interleukins (IL), such as IL-6, IL-4, IL-17,
or IL-12p40, is increased in muscle biopsies of IM subjects
[35–38]. Interactions between cytokines/chemokines and
lymphocytes, suggested to be the link between innate and
adaptive immunity, are likely critical for IM type and stage
[34]; in addition intrinsic mechanisms in skeletal muscle
appear to be highly significant in IM pathogenesis as well.

3. Skeletal Muscle as an Immunoactive Organ
The immunocompetence of nonimmune tissues has been
recognized as determinant to drive the course of immune-
inflammatory processes in several diseases, from organ rejec-
tion to autoimmune pathologies [39, 40]. Skeletal muscle cells
are nowadays considered not only targets of immunological
injury but actual active structures with intrinsic immunolog-
capabilities [41–43].

muscle is now considered as a secretory organ able to pro-
duce and release some cytokines—also termed myokines
within the specific tissue context—to communicate with
other organs, either in physiological conditions, that is, under
contraction [42], or pathological conditions, as in inflam-
mary processes [43].

In particular, chemokines, a class of small cytokines
with potent chemotactic activity, such as IL-8 (CXCL8), Mig
(CXCL9), IP-10 (CXCL10), RANTES (CCL5), and MCP-1
(CCL2), are overexpressed during myositis in infiltrating
inflammatory cells, extracellular matrix, and muscle fibers
[32, 44–47]. Those molecules seem to have relevance for
the immune pathogenesis of IMs because they promote and
facilitate activated Th1 type cell trafficking to muscle tissues.
In line with this view, we have previously confirmed
the importance of TNFα in IMs, suggesting new molecular
insight(s) involving the important role of the chemokine
CXCL10 in muscular inflammation [48, 49].

3.2. CXCL10 in Skeletal Muscle Inflammation. CXCL10 (or
IP-10 10 kD IFNy-induced protein) is a small peptide of
CXC chemokine subfamily known to modulate innate and
adaptive immune responses by controlling leukocyte traf-
ficking [40, 50]. It is secreted by several types of immune
and resident cells under proinflammatory conditions [40].
It is known to polarize T cells towards Th1 type dominance
and seems to be directly associated to disease pathogenesis:
through local tissue accumulation, it triggers and perpetuates
a self-promoting inflammatory loop by interacting with its
specific receptor CXCR3 on T, NK, B cells, macrophages, and DCs [40, 51–54]. Notably, human skeletal muscle cells challenged by inflammatory stimuli secrete significant amount of CXCL10 (virtually absent in basal condition), likely through a TNFα-driven mechanism: TNFα/TNFα receptor (TNFαR) system seems the critical one in promoting muscular inflammation at cellular level in human skeletal muscle cells, involving nuclear transcription factor κB (NF-κB), C-Jun NH2-terminal kinase (JNK), and extracellular signal-regulated kinase (ERK) intracellular path activation [48, 49]. In particular, the specific blockage of NF-κB and JNK signaling significantly reduced CXCL10 secretion [49]. Thus, albeit CXCL10 is by definition an IFNγ-induced chemokine, it seems to be driven almost exclusively by TNFα in inflammatory processes within human skeletal muscle cells. That is, in our opinion, not so surprising.

3.3. The Route of TNFα. TNFα is known as one of the essential cytokines in promoting muscular inflammation at cellular level [55, 56]; it has been recently confirmed to be a key mediator involved in IM pathogenesis and, consequently, emerges as a potential therapeutic target [57–59]. Accordingly, the neutralization of TNFα activity with specific antibodies, TNFαR antagonists, or NF-κB inhibitors has been investigated in experimental animal models of myositis, in vitro and in vivo [60, 61]. Of notice, TNFα pharmacological blockade by the neutralizing antibody infliximab or the soluble TNFαR etanercept, already used in clinics for the treatment of rheumatoid arthritis or Crohn’s disease, has been extended to IMs, although with some caution [62–65]. Thus far, as from our and other’s studies, targeting TNFα, TNFαR II—the subtype mainly engaged in immune response regulation [48, 66, 67]—and TNFα-related pathways—directly associated with CXCL10 production by skeletal muscle cells [49]—might be beneficial for IM treatment.

Hence, the capability of some VDR agonists to target TNFα, as shown by different studies, seems quite intriguing, and we would like to point out VDR agonist skill to selectively impair TNFα signaling during inflammation processes in human skeletal muscle cells.

4. VDR Agonists as Protolerogenic Molecules

It is known that vitamin D plays a role in the control of immune cell function through VDR, with important effects onto the immune-mediated response toward protolerogenic dominance [68–72]. VDR agonists are able to attenuate excessive Th1-driven inflammation and avoid downstream Th1 polarization during inflammatory processes involved in allo- or autoimmune response, that is, in organ transplant rejection or autoimmune diseases, as recently addressed in a review on the topic [39].

Herein, we would like to underline that the protolerogenic activity of VDR relies on their capability to control maturation, differentiation, and activation of different type of immune cells, that is, monocytes, macrophages, B and T lymphocytes, neutrophils, and DC, throughout the activation of VDR, either constitutively present or induced in the majority of the immune cells [73, 74].

Since the pioneering studies by Bhalla et al. [75], VDR agonists have been documented to inhibit selectively Th1 cell development [76, 77] and directly Th1-type cytokines, such as IL-2 and IFNγ [78–80]. In particular, while IL-2 inhibition is linked to an impairment of the transcription factor nuclear factor of activated T cells (NF-AT) complex formation, VDR ligand-induced IFNγ negative regulation has been explained by a direct interaction of the ligand-bound VDR complex with vitamin D responsive element (VDRE) within IFNγ promoter [78–80]. However, some controversy arises against direct effects of VDR ligands onto IFNγ inhibition [81]. Furthermore, T-cell activity can be inhibited by a VDR-mediated indirect mechanism through the downregulation of the expression of the MHC class II molecules and CD40, CD80, and CD86 costimulatory proteins in DC. DC are, indeed, well known targets of VDR ligands, which markedly impair IL-12—by targeting NF-κB, through Rel-B and c-Rel NFκB-related protein [82, 83]—and increase IL-10 production [81, 84–86]. The prevention of DC differentiation and maturation, activation, and survival leads to DC protolerogenic phenotype and function along with T-cell hyporesponsiveness, as shown by in vivo and in vitro studies [87, 88]. By the induction of protolerogenic DC phenotype, VDR ligands seem responsible for CD4+CD25+ regulatory T-cell enhancement [89, 90].

In addition, it is quite clear that VDR ligands directly target also Th17 cell subtype, as shown by the reduction of Th17 cytokines, such as IL-17A, IL-17F, and IL-22 by memory T cells in patients with early rheumatoid arthritis (RA) [91].

An enhanced development of Th2 type cells by VDR agonists throughout a direct effect on naïve CD4+ cells has been reported [92]. A direct enhancement of Th2 type genes (i.e., IL-10, IL-4) is favored by VDR agonists while gene transcription of Th1/Th17 type cytokines (i.e., IL-2, IL-6, IL-12, IL-17, and IL-23) is declined [93, 94]. Therefore, a definite switch of Th1 cell response towards Th2-mediated events occurs. Moreover, since macrophages [91, 95, 96], DC [97], and T cells [91] produce 1,25(OH)2D3, a contribution of this hormone to physiologically regulate innate and adaptive immunity could be speculated.

B cells, due to CYP27b1 (alpha-hydroxylase) expression, have been hypothesized to be capable of autocrine/intracrine synthesis/response to vitamin D as well [98, 99]. In particular, vitamin D seems to predominantly modulate human naïve B cells activation through the VDR target gene cyp24a1 and NF-κB [99] regulation.

So far, the anti-inflammatory feature of VDR agonists exerted onto several types of immune cells depends not only on VDR expression, but, and maybe especially, on the presence of common targets in their signal transduction pathways, such as the NF-κB, downstream of TNFα [83, 100]. NF-κB is a key mediator of cytokine/chemokine-induced inflammation in several types of tissue resident cells and, notably a VDR agonist tissue target as well [48, 101–103] (Figure 1).

5. VDR Agonists as Therapeutic Tools in IMs

Based on the capacity to counteract NF-κB activation also in resident cells, VDR agonists cause a significant reduction
in local release of potent chemotactic factors—cytokines and chemokines—that, in turn, reduces the recruitment of immune cells (Th1 cells, macrophages, and DC) to the site of inflammation [18, 19, 80, 83]. As a result, the mechanisms underlying the self-enhancing inflammatory loop between immune and resident cells are likely impaired. So far, the feature of VDR agonists to counteract the path downstream of TNFα appears particularly relevant in view of a break up during inflammatory processes. Indeed, by interfering with NF-κB nuclear translocation VDR agonists attenuate inflammation in several organ cell types such as adipocytes, thyrocytes, cardiomyocytes, in association to a decrease in proinflammatory cytokine production [20, 21, 104, 105].

We have recently reported on the effect of less-hypercalcemic VDR agonist BXL-01-0029 in human skeletal muscle cells under maximal inflammatory stimuli; it decreases CXCL10 secretion with the highest potency versus other current immunosuppressants and specifically deactivates TNFα pathways: JNK phosphorylation is reduced and, quite remarkably in our opinion, NF-κB activation is prevented, while Stat1 activation, downstream of IFNγ, is unaffected. Hence, it appears that BXL-01-0029-induced inhibition of TNFα signal path may be sufficient to significantly decrease CXCL10 secretion by human skeletal muscle cells. This result seems quite intriguing considering the pivotal role of TNFα in muscular inflammation. Accordingly, in human skeletal muscle cells, differently from other cell types, such as human cardiomyocytes, thyrocytes, and renal cells, CXCL10 secretion seems to be essentially dependent on TNFα-driven mechanisms.

As previously addressed, counteracting TNFα signal and, therefore, CXCL10 local accumulation might result in a relevant crumble in the self-enhancing inflammatory loop established between immune infiltrating cells and resident muscular cells. This effect appears even more significant when considering the limited efficacy of the current immunosuppressants in controlling inflammation in IMs.

An additional consequence of TNFα detrimental effects is a possible dysregulation of mitochondrial metabolic pathways occurring in inflammatory muscle diseases [106, 107]: abnormalities in energy regulating paths and deficiencies in glycolytic enzymes have been often observed in IM fibers with more pronounced damages [108, 109]. Even though those mechanisms have still to be fully clarified, myoblasts, immature myofibers, and proinflammatory cytokines, such as TNFα and IL-15, seem the focal point for a cross talk between muscle inflammation and metabolism [34]. So far, targeting proinflammatory muscular cytokines secretion directly in myoblasts may be a quite helpful therapeutic strategy, considering the different possible beneficial effects.

The potential therapeutic application of BXL-01-0029 has been previously shown in nonobese diabetic (NOD) mice, who develop a pathogenesis similar to the human autoimmune type 1 diabetes (T1D), where VDR agonist-induced
block of NF-κB nuclear translocation in pancreatic islets is associated to a significant decrease both in Th1 cell organ infiltration and CXCL10 secretion [110]. We have also previously reported that BXL-01-0029 could be a potential steroid-sparing agent in the current immunosuppressant cocktails used to control inflammation in heart or renal rejection after transplantation [21, 101]. Notably, BXL-01-0029 similarly to elocalcitol, another nonhypercalcemic VDR agonist, does not affect cell viability in several types of organ resident cells and in CD4+ T cells, while significantly decreasing Th1- and Th17-cytokine secretion [20, 101]. Conversely, the majority of immunosuppressants have been designed to reduce the number of immune cells; this specific effect accomplishes the appearance of the well known noxious side effects of immunosuppressive drugs, that is, from metabolic disturbances, to opportunistic infections or tumor development [13–15]. So far, VDR agonists are likely able to control immune reaction acting essentially onto the production of mediators of inflammation, cytokines, and chemokines.

It cannot be ignored that circulating cytokine level are related also to the disease stage, such as acute or chronic, reflecting Th1 or Th2 dominance; in this regard, and in line with a previous study in IM patients in active phase of the diseases [111], we have recently reported that, in sera of subjects at time of diagnosis with IMs CXCL10 is higher than in matched controls, and, importantly, is the highest as compared to some other circulating Th1 cytokines—such as TNFα, IFNγ, IL-8, IL-6, MCP-1, MIP-1β (Th1 type), and IL-10 (Th2 type) [49]. Indeed, CXCL10, as Th1 type chemokine, participates to the early events in inflammatory/immune response and, even more important, is thought to trigger the reaction next to the antigenic challenge [54]. So far, we speculate that pharmacological targeting systemic and especially local muscular CXCL10 production with VDR agonists could result a particularly advantageous approach from the early stage of myositis.

6. Remarks and Conclusion

VDR agonists exert overall repressive effects onto Th1 polarized immune response, which dominates in inflammation, toward a more regulatory Th2 phenotype molecules, which dominate in tolerogenicity. Albeit the current controversy regarding VDR expression in adult skeletal muscle [112], as from our and other data, it appears that VDR agonists exert rapid anti-inflammatory effects directly in skeletal muscle cells. Whether VDR is expressed in skeletal muscle is still a debated issue [1, 112, 113]; the lower basal level in muscle as compared to duodenal cells—widely used as positive control—has been suggested as a possible cause of missing VDR detection in muscle cells [114]. Studies onto contractility and myogenesis showed that VDR is present and engaged in rapid nongenomic vitamin D-induced activation of tyrosine phosphorylation cascade in muscle cells [115]. Several lines of evidence indicate a membrane-associated VDR as the mediator of vitamin D-induced rapid events and, recently, the classical VDR located in caveolae has been shown to mediate vitamin D fast nongenomic signaling in skeletal muscle [114]. The existence of another cell surface receptor for vitamin D, named membrane associated, rapid response steroid binding (MARRS) has been reported in muscle [116].

Albeit the question on whether VDR exists in fully differentiated muscle or plays its pivotal role in myogenesis still is to be clarified, it is undeniable that vitamin D supplementation ameliorates proximal myopathy and muscle pain in patients with severe vitamin D deficiency [2, 117, 118]. Many reports on interventional studies are controversial; however vitamin D supplementation has been shown to improve musculoskeletal function in 12 weeks and reduce the risk of falls after 2 years in institutionalized subjects [5, 6, 119]. Based on their capability to balance immune system homeostasis, without being classical “immunosuppressants,” and target local inflammatory mediators at muscular level, VDR ligands appear to be optimal candidates as novel therapeutic agents for IMs. Furthermore, additional benefits of VDR agonists are related to their protective effects against bone-loss, infective pathogens, neoplasies [120–122], all side effects of immunosuppressive agents. Nevertheless, the use of VDR agonists in clinics is generally not pursued and is limited to calcipotriol, a drug applied for psoriasis topic treatment [123].

In fact, despite many advantages, the limit in therapeutic applications of vitamin D and vitamin D analogues undeniably relies on the systemic toxicity often associated with long-term intake: hypercalcemia is the main risk associated to the supraphysiological doses of vitamin D necessary to reach the low local effective concentration [124, 125]. Thus, the introduction of new molecules with immunosuppressive features without causing significant hypercalcemia has been strongly encouraged [126]. For this reason, drug development has been focusing on designing VDR agonists with a distinct separation between immunomodulatory and hypercalcemic potency. The selectivity is function of altered pharmacokinetics in comparison with the natural counterpart but, albeit quite many molecules eliciting much less calcemic effects have been developed, still discrepancies emerge between the therapeutic potential, as set in experimental work, and clinical data [127]. Those frustrating results may also depend on the lack of large and well designed trials.

Molecules with less or none hypercalcemic activity, as BXL-01-0029 or elocalcitol, could be suitable candidates—even as steroid-sparing agents—for inclusion in the therapeutic regimens for IMs. In particular, elocalcitol (150 µg/day P.O.) safety and tolerability in terms of calcemic effect has been proven in double-blind randomized study in 101 postmenopausal osteoporotic women, in placebo-controlled phase IIa (119 enrolled subjects) and follow-on phase IIb (514 patients) trial for the treatment of benign prostate hyperplasia (BPH) [128, 129]. Further studies bridging basic, clinic, and pharmacological researches seem mandatory and local administration strategies could be envisioned for IM treatment to overcome systemic drug intake.

As previously stated, inadequate response to therapy and, consequently, poor outcome are often encountered by IM patients. The major concern in clinics is the absence of internationally validated evaluation criteria to conduct randomized controlled trials [14, 15]; in fact, the few validated assessment tools available provide limited information helpful to patient management. To overcome this limit,
multidisciplinary consortiums, such as the International Myositis Assessment and Clinical Studies Group (IMACS, http://www.niehs.nih.gov/research/resources/imacs/), or Paediatric Rheumatology International Trials Organization (PRINTO, https://www.printo.it/)—including rheumatologists, neurologists, physiatrists dermatologists, and other myositis experts—have been established to develop consensus and standards for the conduct and reporting of myositis [14]. Albeit recent advances in understanding the pathogenesis of myositis are unquestionably important, adequate multicentre trials with validated outcome measures represent a must to be pursued in order to define the best treatment for IMs and give clinical remission as a realistic objective to IM patients.

**Conflict of Interests**

The author declares that there is no conflict of interests regarding the publication of this paper.

**References**


BioMedResearchInternational


